You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSevoflurane
Accession NumberDB01236  (APRD00219)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionSevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia]
Structure
Thumb
Synonyms
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Sevofluran
Sevoflurane
Sevoflurano
Sevofluranum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sevofluraneliquid99.97 %inhalationBaxter Corporation2007-04-11Not applicableCanada
Sevorane AFliquid99.97 %inhalationAbbvie Corporation1995-12-31Not applicableCanada
Sojourn Sevofluraneliquid99.97 %inhalationPiramal Critical Care Inc2009-11-18Not applicableCanada
Ultaneliquid250 mL/250mLrespiratory (inhalation)Abb Vie Inc.1995-06-07Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sevofluraneliquid250 mL/250mLrespiratory (inhalation)Baxter Healthcare Corporation2011-10-18Not applicableUs
Sevofluraneliquid250 mL/250mLrespiratory (inhalation)Sandoz Inc.2015-11-03Not applicableUs
Sevofluraneliquid250 mL/250mLrespiratory (inhalation)Baxter Healthcare Corporation2002-07-07Not applicableUs
Sevofluraneliquid1 mL/mLrespiratory (inhalation)Piramal Critical Care Inc2011-07-15Not applicableUs
Sojournliquid1 mL/mLrespiratory (inhalation)Piramal Critical Care Inc2010-04-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SevoraneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII38LVP0K73A
CAS number28523-86-6
WeightAverage: 200.0548
Monoisotopic: 200.007212153
Chemical FormulaC4H3F7O
InChI KeyInChIKey=DFEYYRMXOJXZRJ-UHFFFAOYSA-N
InChI
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
IUPAC Name
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
SMILES
FCOC(C(F)(F)F)C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassEthers
Sub ClassDialkyl ethers
Direct ParentDialkyl ethers
Alternative Parents
Substituents
  • Dialkyl ether
  • Halomethane
  • Hydrocarbon derivative
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Pharmacology
IndicationUsed for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
PharmacodynamicsSevoflurane (also called fluoromethyl) is a halogenated ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. It is often administered in nitrous oxide and pure oxygen. After desflurane it is the volatile anesthetic with the fastest onset and offset. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionSevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor, and the glycine receptor.
Related Articles
AbsorptionRapidly absorbed into circulation via the lungs, however solubility in the blood is low.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Relatively little biotransformation, only 5% is metabolized by cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. No other metabolic pathways have been identified for sevoflurane.

SubstrateEnzymesProduct
Sevoflurane
Not Available
FluorideDetails
Sevoflurane
Not Available
Carbon dioxideDetails
Sevoflurane
Not Available
HexafluoroisopropanolDetails
Route of eliminationThe low solubility of sevoflurane facilitates rapid elimination via the lungs. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride.
Half life15-23 hours
ClearanceNot Available
ToxicityLC50=49881 ppm/hr (rat), LD50=10.8 g/kg (rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.9941
Caco-2 permeable+0.6134
P-glycoprotein substrateNon-substrate0.8839
P-glycoprotein inhibitor INon-inhibitor0.8807
P-glycoprotein inhibitor IINon-inhibitor0.5436
Renal organic cation transporterNon-inhibitor0.8649
CYP450 2C9 substrateNon-substrate0.9039
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6876
CYP450 1A2 substrateInhibitor0.5254
CYP450 2C9 inhibitorNon-inhibitor0.7941
CYP450 2D6 inhibitorNon-inhibitor0.9114
CYP450 2C19 inhibitorInhibitor0.5569
CYP450 3A4 inhibitorNon-inhibitor0.9148
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7006
Ames testAMES toxic0.5082
CarcinogenicityCarcinogens 0.7014
BiodegradationNot ready biodegradable0.8564
Rat acute toxicity1.3361 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9485
hERG inhibition (predictor II)Non-inhibitor0.8685
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Liquidinhalation99.97 %
Liquidrespiratory (inhalation)1 mL/mL
Liquidrespiratory (inhalation)250 mL/250mL
Prices
Unit descriptionCostUnit
Ultane 250 ml pen bottle1.16USD ml
Sojourn inhalation liquid0.99USD ml
Sevoflurane inhalation liquid0.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5990176 Yes1997-07-272017-07-27Us
US6074668 Yes1998-07-092018-07-09Us
US6288127 Yes1997-07-272017-07-27Us
US6444859 Yes1997-07-272017-07-27Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point58.5 °CPhysProp
water solubilityVery slightly solubleNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.48 mg/mLALOGPS
logP2.44ALOGPS
logP2.27ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)15.07ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity23.3 m3·mol-1ChemAxon
Polarizability9.83 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ross C. Terrell, “Method for the preparation of sevoflurane.” U.S. Patent US5969193, issued December, 1979.

US5969193
General ReferencesNot Available
External Links
ATC CodesN01AB08
AHFS Codes
  • 28:04.00
PDB EntriesNot Available
FDA labelDownload (188 KB)
MSDSDownload (49.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with 7-Nitroindazole.
AbciximabSevoflurane may increase the anticoagulant activities of Abciximab.
AbciximabAbciximab may increase the antiplatelet activities of Sevoflurane.
AcenocoumarolSevoflurane may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aceprometazine.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may increase the antiplatelet activities of Sevoflurane.
adipiplonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sevoflurane.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sevoflurane.
AlprostadilAlprostadil may increase the antiplatelet activities of Sevoflurane.
AlteplaseSevoflurane may increase the anticoagulant activities of Alteplase.
ALX-0081Sevoflurane may increase the anticoagulant activities of ALX-0081.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aminosalicylic Acid.
AmiodaroneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.
AmiodaroneSevoflurane may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amperozide.
AnagrelideSevoflurane may increase the anticoagulant activities of Anagrelide.
AnagrelideAnagrelide may increase the antiplatelet activities of Sevoflurane.
AncrodSevoflurane may increase the anticoagulant activities of Ancrod.
AnistreplaseSevoflurane may increase the anticoagulant activities of Anistreplase.
Antithrombin III humanSevoflurane may increase the anticoagulant activities of Antithrombin III human.
ApixabanSevoflurane may increase the anticoagulant activities of Apixaban.
AprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Aprepitant.
ArdeparinSevoflurane may increase the anticoagulant activities of Ardeparin.
ArgatrobanSevoflurane may increase the anticoagulant activities of Argatroban.
ArgatrobanArgatroban may increase the antiplatelet activities of Sevoflurane.
AripiprazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aripiprazole.
Arsenic trioxideSevoflurane may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherSevoflurane may increase the QTc-prolonging activities of Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Asenapine.
AstaxanthinSevoflurane may increase the anticoagulant activities of Astaxanthin.
AtazanavirThe metabolism of Sevoflurane can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.
Atracurium besylateSevoflurane may increase the neuromuscular blocking activities of Atracurium besylate.
AzaperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azaperone.
AzelastineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Sevoflurane.
AzithromycinSevoflurane may increase the QTc-prolonging activities of Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.
BatroxobinSevoflurane may increase the anticoagulant activities of Batroxobin.
BecaplerminSevoflurane may increase the anticoagulant activities of Becaplermin.
BedaquilineSevoflurane may increase the QTc-prolonging activities of Bedaquiline.
BemiparinSevoflurane may increase the anticoagulant activities of Bemiparin.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sevoflurane.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benzyl alcohol.
BeraprostSevoflurane may increase the anticoagulant activities of Beraprost.
BeraprostBeraprost may increase the antiplatelet activities of Sevoflurane.
BexaroteneThe serum concentration of Sevoflurane can be decreased when it is combined with Bexarotene.
BivalirudinSevoflurane may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Sevoflurane can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Sevoflurane can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Sevoflurane can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
BrimonidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Sevoflurane.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane.
ButacaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.
CangrelorSevoflurane may increase the anticoagulant activities of Cangrelor.
CangrelorCangrelor may increase the antiplatelet activities of Sevoflurane.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sevoflurane.
CarbinoxamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carisoprodol.
CeritinibThe serum concentration of Sevoflurane can be increased when it is combined with Ceritinib.
CeritinibSevoflurane may increase the QTc-prolonging activities of Ceritinib.
CertoparinSevoflurane may increase the anticoagulant activities of Certoparin.
CetirizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sevoflurane.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sevoflurane.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sevoflurane.
ChloroquineSevoflurane may increase the QTc-prolonging activities of Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorphenamine.
ChlorpromazineSevoflurane may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sevoflurane.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorzoxazone.
CilostazolSevoflurane may increase the anticoagulant activities of Cilostazol.
CilostazolCilostazol may increase the antiplatelet activities of Sevoflurane.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sevoflurane.
CiprofloxacinSevoflurane may increase the QTc-prolonging activities of Ciprofloxacin.
CisaprideSevoflurane may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Citalopram.
CitalopramThe metabolism of Sevoflurane can be decreased when combined with Citalopram.
Citric AcidSevoflurane may increase the anticoagulant activities of Citric Acid.
ClarithromycinSevoflurane may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Sevoflurane can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonidine.
ClopidogrelSevoflurane may increase the anticoagulant activities of Clopidogrel.
ClopidogrelThe metabolism of Sevoflurane can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.
ClotrimazoleThe metabolism of Sevoflurane can be decreased when combined with Clotrimazole.
ClozapineSevoflurane may increase the QTc-prolonging activities of Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sevoflurane.
CobicistatThe metabolism of Sevoflurane can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Sevoflurane.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sevoflurane.
CollagenaseThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Collagenase.
ConivaptanThe serum concentration of Sevoflurane can be increased when it is combined with Conivaptan.
CrizotinibSevoflurane may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Sevoflurane can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.
CyclosporineThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Sevoflurane can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.
DalteparinSevoflurane may increase the anticoagulant activities of Dalteparin.
DanaparoidSevoflurane may increase the anticoagulant activities of Danaparoid.
DantroleneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sevoflurane.
DapoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapoxetine.
DarunavirThe metabolism of Sevoflurane can be decreased when combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Sevoflurane.
DeferasiroxThe serum concentration of Sevoflurane can be decreased when it is combined with Deferasirox.
DefibrotideSevoflurane may increase the anticoagulant activities of Defibrotide.
DefibrotideDefibrotide may increase the antiplatelet activities of Sevoflurane.
DelavirdineThe metabolism of Sevoflurane can be decreased when combined with Delavirdine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Deoxycholic Acid.
deramciclaneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane.
DesipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desipramine.
DesirudinSevoflurane may increase the anticoagulant activities of Desirudin.
DesloratadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desloratadine.
DesmoteplaseSevoflurane may increase the anticoagulant activities of Desmoteplase.
DetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Detomidine.
DexamethasoneThe serum concentration of Sevoflurane can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sevoflurane.
DextranSevoflurane may increase the anticoagulant activities of Dextran.
Dextran 40Sevoflurane may increase the anticoagulant activities of Dextran 40.
Dextran 70Sevoflurane may increase the anticoagulant activities of Dextran 70.
Dextran 75Sevoflurane may increase the anticoagulant activities of Dextran 75.
DextromoramideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sevoflurane.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Sevoflurane.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sevoflurane.
DicoumarolSevoflurane may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Difenoxin.
DiflunisalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.
DihydrocodeineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Sevoflurane can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.
DiltiazemThe metabolism of Sevoflurane can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sevoflurane.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sevoflurane.
DipyridamoleSevoflurane may increase the anticoagulant activities of Dipyridamole.
DipyridamoleDipyridamole may increase the antiplatelet activities of Sevoflurane.
DisopyramideSevoflurane may increase the QTc-prolonging activities of Disopyramide.
DisulfiramThe metabolism of Sevoflurane can be decreased when combined with Disulfiram.
DitazoleSevoflurane may increase the anticoagulant activities of Ditazole.
DofetilideSevoflurane may increase the QTc-prolonging activities of Dofetilide.
DolasetronSevoflurane may increase the QTc-prolonging activities of Dolasetron.
DomperidoneSevoflurane may increase the QTc-prolonging activities of Domperidone.
DopamineSevoflurane may increase the arrhythmogenic activities of Dopamine.
DoramectinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxepin.
DoxorubicinThe metabolism of Sevoflurane can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Sevoflurane can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
DoxylamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Sevoflurane is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
DronedaroneThe metabolism of Sevoflurane can be decreased when combined with Dronedarone.
DronedaroneSevoflurane may increase the QTc-prolonging activities of Dronedarone.
DroperidolSevoflurane may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Sevoflurane.
DrotebanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Drotebanol.
Drotrecogin alfaSevoflurane may increase the anticoagulant activities of Drotrecogin alfa.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.
EcgonineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Sevoflurane is combined with ECGONINE METHYL ESTER.
Edetic AcidSevoflurane may increase the anticoagulant activities of Edetic Acid.
EdoxabanSevoflurane may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Sevoflurane can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Efavirenz.
EliglustatSevoflurane may increase the QTc-prolonging activities of Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sevoflurane.
EnoxaparinSevoflurane may increase the anticoagulant activities of Enoxaparin.
EntacaponeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Entacapone.
EnzalutamideThe serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.
EphedraEphedra may increase the arrhythmogenic activities of Sevoflurane.
EphedrineEphedrine may increase the arrhythmogenic activities of Sevoflurane.
EpinastineEpinastine may increase the antiplatelet activities of Sevoflurane.
EpinephrineSevoflurane may increase the arrhythmogenic activities of Epinephrine.
EpoprostenolSevoflurane may increase the anticoagulant activities of Epoprostenol.
EpoprostenolEpoprostenol may increase the antiplatelet activities of Sevoflurane.
EptifibatideSevoflurane may increase the anticoagulant activities of Eptifibatide.
EptifibatideEptifibatide may increase the antiplatelet activities of Sevoflurane.
ErythromycinSevoflurane may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Sevoflurane can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Sevoflurane can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sevoflurane.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sevoflurane.
EthanolSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Sevoflurane.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.
EthosuximideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethotoin.
Ethyl biscoumacetateSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sevoflurane.
EtoperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etorphine.
EtravirineThe serum concentration of Sevoflurane can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.
FexofenadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fexofenadine.
FibrinolysinSevoflurane may increase the anticoagulant activities of Fibrinolysin.
FlecainideSevoflurane may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flibanserin.
FluconazoleThe metabolism of Sevoflurane can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Sevoflurane.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane.
FluspirileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluvoxamine.
FluvoxamineThe metabolism of Sevoflurane can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumSevoflurane may increase the anticoagulant activities of Fondaparinux sodium.
FormoterolSevoflurane may increase the arrhythmogenic activities of Formoterol.
FosamprenavirThe metabolism of Sevoflurane can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fospropofol.
Fusidic AcidThe serum concentration of Sevoflurane can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with gabapentin enacarbil.
Gadobenic acidSevoflurane may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gamma Hydroxybutyric Acid.
GemifloxacinSevoflurane may increase the QTc-prolonging activities of Gemifloxacin.
GlucosamineGlucosamine may increase the antiplatelet activities of Sevoflurane.
GlutethimideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Glutethimide.
GoserelinSevoflurane may increase the QTc-prolonging activities of Goserelin.
GranisetronSevoflurane may increase the QTc-prolonging activities of Granisetron.
GuanfacineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sevoflurane.
HaloperidolSevoflurane may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sevoflurane.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sevoflurane.
HeparinSevoflurane may increase the anticoagulant activities of Heparin.
HeroinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hexobarbital.
HirulogSevoflurane may increase the anticoagulant activities of Hirulog.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Sevoflurane.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
HydroxyzineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hydroxyzine.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sevoflurane.
IbudilastSevoflurane may increase the antiplatelet activities of Ibudilast.
IbutilideSevoflurane may increase the QTc-prolonging activities of Ibutilide.
Icosapent ethylSevoflurane may increase the antiplatelet activities of Icosapent ethyl.
IdelalisibThe serum concentration of Sevoflurane can be increased when it is combined with Idelalisib.
IfenprodilSevoflurane may increase the antiplatelet activities of Ifenprodil.
IloperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Iloperidone.
IloprostSevoflurane may increase the anticoagulant activities of Iloprost.
IloprostIloprost may increase the antiplatelet activities of Sevoflurane.
ImatinibThe metabolism of Sevoflurane can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.
IndinavirThe metabolism of Sevoflurane can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Sevoflurane can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sevoflurane.
IsoniazidThe metabolism of Sevoflurane can be decreased when combined with Isoniazid.
IsoprenalineSevoflurane may increase the arrhythmogenic activities of Isoprenaline.
IsradipineThe metabolism of Sevoflurane can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Sevoflurane can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Sevoflurane can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.
KetazolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketobemidone.
KetoconazoleThe metabolism of Sevoflurane can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.
LenvatinibSevoflurane may increase the QTc-prolonging activities of Lenvatinib.
LepirudinSevoflurane may increase the anticoagulant activities of Lepirudin.
LeuprolideSevoflurane may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sevoflurane.
LevocabastineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levodopa.
LevofloxacinSevoflurane may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sevoflurane.
LevomilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sevoflurane.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sevoflurane.
LimaprostLimaprost may increase the antiplatelet activities of Sevoflurane.
LithiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lofentanil.
LopinavirThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.
LopinavirSevoflurane may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sevoflurane.
LovastatinThe metabolism of Sevoflurane can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.
Lu AA21004The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lu AA21004.
LuliconazoleThe serum concentration of Sevoflurane can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Sevoflurane can be decreased when it is combined with Lumacaftor.
LumefantrineSevoflurane may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Sevoflurane.
MelperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sevoflurane.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.
MesalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesalazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sevoflurane.
MetaxaloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.
MethadoneSevoflurane may increase the QTc-prolonging activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sevoflurane.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sevoflurane.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sevoflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.
MethylphenidateMethylphenidate may increase the hypertensive activities of Sevoflurane.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sevoflurane.
MetyrosineSevoflurane may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.
MifepristoneThe metabolism of Sevoflurane can be decreased when combined with Mifepristone.
MifepristoneSevoflurane may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Milnacipran.
MilrinoneMilrinone may increase the antiplatelet activities of Sevoflurane.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
MirtazapineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sevoflurane.
MitotaneThe serum concentration of Sevoflurane can be decreased when it is combined with Mitotane.
MivacuriumSevoflurane may increase the neuromuscular blocking activities of Mivacurium.
ModafinilThe serum concentration of Sevoflurane can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.
MoxifloxacinSevoflurane may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
NabiloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nabilone.
NadroparinSevoflurane may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Sevoflurane can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sevoflurane.
NCX 4016Sevoflurane may increase the anticoagulant activities of NCX 4016.
NCX 4016NCX 4016 may increase the antiplatelet activities of Sevoflurane.
NefazodoneThe metabolism of Sevoflurane can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Sevoflurane can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Sevoflurane can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Sevoflurane can be decreased when combined with Nevirapine.
NicotineThe metabolism of Sevoflurane can be decreased when combined with Nicotine.
NilotinibThe metabolism of Sevoflurane can be decreased when combined with Nilotinib.
NilotinibSevoflurane may increase the QTc-prolonging activities of Nilotinib.
NimesulideSevoflurane may increase the antiplatelet activities of Nimesulide.
NitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrous oxide.
NorepinephrineSevoflurane may increase the arrhythmogenic activities of Norepinephrine.
NormethadoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.
OfloxacinSevoflurane may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olanzapine.
OlaparibThe metabolism of Sevoflurane can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olopatadine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Sevoflurane.
OndansetronSevoflurane may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sevoflurane.
OpiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Opium.
OrphenadrineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sevoflurane.
OsanetantThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.
OsimertinibThe serum concentration of Sevoflurane can be increased when it is combined with Osimertinib.
OtamixabanSevoflurane may increase the anticoagulant activities of Otamixaban.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sevoflurane.
OxprenololThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sevoflurane.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sevoflurane.
PalbociclibThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paliperidone.
PanobinostatSevoflurane may increase the QTc-prolonging activities of Panobinostat.
ParaldehydeSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Sevoflurane.
ParnaparinSevoflurane may increase the anticoagulant activities of Parnaparin.
ParoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paroxetine.
ParoxetineThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.
PazopanibSevoflurane may increase the QTc-prolonging activities of Pazopanib.
PentamidineSevoflurane may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Sevoflurane.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.
Pentosan PolysulfateSevoflurane may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Sevoflurane.
PerampanelThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perampanel.
PerflutrenSevoflurane may increase the QTc-prolonging activities of Perflutren.
PerospironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sevoflurane.
PhenindioneSevoflurane may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sevoflurane.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenoxyethanol.
PhenprocoumonSevoflurane may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Sevoflurane.
PipamperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pizotifen.
PlasminSevoflurane may increase the anticoagulant activities of Plasmin.
PomalidomideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.
PosaconazoleThe metabolism of Sevoflurane can be decreased when combined with Posaconazole.
PramipexoleSevoflurane may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pramocaine.
PrasugrelSevoflurane may increase the anticoagulant activities of Prasugrel.
PrasugrelPrasugrel may increase the antiplatelet activities of Sevoflurane.
PrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sevoflurane.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sevoflurane.
PrimaquineSevoflurane may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Primidone.
ProcainamideSevoflurane may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sevoflurane.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.
PromazineSevoflurane may increase the QTc-prolonging activities of Promazine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sevoflurane.
PromethazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Promethazine.
PropafenoneSevoflurane may increase the QTc-prolonging activities of Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sevoflurane.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.
PropoxycaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Propoxycaine.
Protein CSevoflurane may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeSevoflurane may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Sevoflurane is combined with PSD502.
QuazepamThe serum concentration of Sevoflurane can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sevoflurane.
QuinidineSevoflurane may increase the QTc-prolonging activities of Quinidine.
QuinineSevoflurane may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ramelteon.
RanolazineThe metabolism of Sevoflurane can be decreased when combined with Ranolazine.
RapacuroniumSevoflurane may increase the neuromuscular blocking activities of Rapacuronium.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sevoflurane.
ResveratrolSevoflurane may increase the antiplatelet activities of Resveratrol.
ReteplaseSevoflurane may increase the anticoagulant activities of Reteplase.
ReviparinSevoflurane may increase the anticoagulant activities of Reviparin.
RidogrelRidogrel may increase the antiplatelet activities of Sevoflurane.
RifabutinThe metabolism of Sevoflurane can be increased when combined with Rifabutin.
RifampicinThe metabolism of Sevoflurane can be increased when combined with Rifampicin.
RifapentineThe metabolism of Sevoflurane can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sevoflurane.
RitonavirThe metabolism of Sevoflurane can be decreased when combined with Ritonavir.
RivaroxabanSevoflurane may increase the anticoagulant activities of Rivaroxaban.
RomifidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Romifidine.
RopiniroleSevoflurane may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane.
RosiglitazoneSevoflurane may increase the anticoagulant activities of Rosiglitazone.
RotigotineSevoflurane may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sevoflurane.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Sevoflurane is combined with S-Ethylisothiourea.
Salicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Salicylic acid.
SaquinavirSevoflurane may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe metabolism of Sevoflurane can be decreased when combined with Saquinavir.
SCH-530348Sevoflurane may increase the antiplatelet activities of SCH-530348.
ScopolamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.
SelexipagSevoflurane may increase the anticoagulant activities of Selexipag.
SertindoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertraline.
SertralineThe metabolism of Sevoflurane can be decreased when combined with Sertraline.
SildenafilThe metabolism of Sevoflurane can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Sevoflurane can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Sevoflurane can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sodium oxybate.
SorafenibThe metabolism of Sevoflurane can be decreased when combined with Sorafenib.
SotalolSevoflurane may increase the QTc-prolonging activities of Sotalol.
SRT501Sevoflurane may increase the antiplatelet activities of SRT501.
St. John's WortThe serum concentration of Sevoflurane can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Stiripentol.
StreptokinaseSevoflurane may increase the anticoagulant activities of Streptokinase.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.
SulfisoxazoleSevoflurane may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Sevoflurane can be decreased when combined with Sulfisoxazole.
SulodexideSevoflurane may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sevoflurane.
SuvorexantThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tasimelteon.
TelaprevirThe metabolism of Sevoflurane can be decreased when combined with Telaprevir.
TelavancinSevoflurane may increase the QTc-prolonging activities of Telavancin.
TelithromycinSevoflurane may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Sevoflurane can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sevoflurane.
TenecteplaseSevoflurane may increase the anticoagulant activities of Tenecteplase.
TesmilifeneSevoflurane may increase the antiplatelet activities of Tesmilifene.
TetrabenazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrodotoxin.
ThalidomideSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sevoflurane.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sevoflurane.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sevoflurane.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sevoflurane.
ThiotepaThe metabolism of Sevoflurane can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiagabine.
TicagrelorSevoflurane may increase the anticoagulant activities of Ticagrelor.
TiclopidineSevoflurane may increase the anticoagulant activities of Ticlopidine.
TiclopidineThe metabolism of Sevoflurane can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiletamine.
TinzaparinSevoflurane may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the antiplatelet activities of Sevoflurane.
TirofibanSevoflurane may increase the anticoagulant activities of Tirofiban.
TirofibanTirofiban may increase the antiplatelet activities of Sevoflurane.
TizanidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.
TocilizumabThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Topiramate.
ToremifeneSevoflurane may increase the QTc-prolonging activities of Toremifene.
TositumomabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.
TranilastSevoflurane may increase the antiplatelet activities of Tranilast.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sevoflurane.
TrapidilSevoflurane may increase the antiplatelet activities of Trapidil.
TrazodoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trazodone.
TreprostinilSevoflurane may increase the anticoagulant activities of Treprostinil.
TreprostinilTreprostinil may increase the antiplatelet activities of Sevoflurane.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sevoflurane.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sevoflurane.
TriflusalSevoflurane may increase the anticoagulant activities of Triflusal.
TriflusalTriflusal may increase the antiplatelet activities of Sevoflurane.
TrimipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Triprolidine.
UrokinaseSevoflurane may increase the anticoagulant activities of Urokinase.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sevoflurane.
VandetanibSevoflurane may increase the QTc-prolonging activities of Vandetanib.
VemurafenibSevoflurane may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Sevoflurane can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Sevoflurane can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vilazodone.
Vitamin EVitamin E may increase the antiplatelet activities of Sevoflurane.
VorapaxarSevoflurane may increase the anticoagulant activities of Vorapaxar.
VorapaxarVorapaxar may increase the antiplatelet activities of Sevoflurane.
VoriconazoleThe metabolism of Sevoflurane can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vortioxetine.
WarfarinSevoflurane may increase the anticoagulant activities of Warfarin.
XimelagatranSevoflurane may increase the anticoagulant activities of Ximelagatran.
XylazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.
ZiconotideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zimelidine.
ZiprasidoneThe metabolism of Sevoflurane can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Sevoflurane.
ZonisamideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sevoflurane.
ZotepineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 03:40